These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 11372025

  • 1. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.
    J Infect Dis; 2001 Jun 15; 183(12):1732-8. PubMed ID: 11372025
    [Abstract] [Full Text] [Related]

  • 2. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A, Pediatric AIDS Clinical Trials Group 377 Study Team.
    Clin Infect Dis; 2002 Apr 01; 34(7):991-1001. PubMed ID: 11880966
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM.
    J Infect Dis; 2000 Feb 01; 181(2):491-7. PubMed ID: 10669331
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP.
    Pediatr Infect Dis J; 2005 Oct 01; 24(10):880-5. PubMed ID: 16220085
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E.
    J Infect Dis; 2004 Jan 01; 189(1):51-60. PubMed ID: 14702153
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec 01; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 12. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J, Yue J, Wu S, Yan Y.
    Arch Virol; 2007 Dec 01; 152(10):1799-805. PubMed ID: 17619115
    [Abstract] [Full Text] [Related]

  • 13. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
    Wiznia A, Stanley K, Krogstad P, Johnson G, Lee S, McNamara J, Moye J, Jackson JB, Mendez H, Aguayo R, Dieudonne A, Kovacs A, Bamji M, Abrams E, Rana S, Sever J, Nachman S.
    AIDS Res Hum Retroviruses; 2000 Aug 10; 16(12):1113-21. PubMed ID: 10954886
    [Abstract] [Full Text] [Related]

  • 14. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 10; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 15. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
    King MS, Bernstein BM, Walmsley SL, Sherer R, Feinberg J, Sanne I, Cernohous P, Montaner JS, Brun SC, Sun E.
    J Infect Dis; 2004 Jul 15; 190(2):280-4. PubMed ID: 15216462
    [Abstract] [Full Text] [Related]

  • 16. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr 15; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 17. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Apr 15; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Apr 15; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 19. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S.
    Southeast Asian J Trop Med Public Health; 2009 Jan 15; 40(1):83-8. PubMed ID: 19323038
    [Abstract] [Full Text] [Related]

  • 20. [Drug combination therapy for children infected with HIV/AIDS--own experience].
    Prandota-Schoepp A, Klinowska-Skupniewska J.
    Przegl Epidemiol; 2001 Jan 15; 55 Suppl 3():135-41. PubMed ID: 11984940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.